- Home
- TULP vs LTRN Comparison
TULP vs LTRN Comparison
Compare TULP & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TULP | LTRN |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TULP | LTRN |
|---|---|---|
| Price | $3.76 | $3.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 233.0K |
| Earning Date | 02-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $1.11 |
| 52 Week High | $4.79 | $5.74 |
Technical Indicators
Market Signals| Indicator | TULP | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 61.75 |
| Support Level | $3.62 | $3.81 |
| Resistance Level | $4.12 | $4.70 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 44.83 | 63.47 |
Price Performance
Historical ComparisonAbout TULP Bloomia Holdings Inc. Common Stock
Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.